We are a biotechnology company with a proprietary epigenetic biomarker discovery platform, EpiSwitch®, based on the latest advances in regulatory genome architecture and its link to clinical outcomes and patient stratification.

EpiSwitch® biomarkers based on chromosomal conformation signatures are a critical cog in personalised medicine.

Technology to select the right drug at the right dose at the right time for the right patient.

Our Publications on EpiSwitch®

PerkinElmer releases application note outlining the importance of EpiSwitch® technology in determining epigenetic biomarkers using the LabChip GX Touch Platform.

OBD and PerkinElmer
Application Note; 25 August 2017

September 20, 2017

https://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/013589_01EpiGenetics-Biomarkers-APP.pdf

Super-Enhancers and Broad H3K4me3 Domains Form Complex Gene Regulatory Circuits Involving Chromatin Interactions.

Cao, F, et. al.,
Scientific Reports

May 30, 2017

https://www.nature.com/articles/s41598-017-02257-3

Chromatin Conformation Signatures Associated with Epigenetic Deregulation of the FIP1L1 and PDGFRA Genes.

Grand, FH, et. al.,
American Society of Haematology

December 6, 2016

https://ash.confex.com/ash/2016/webprogram/Paper90884.html

Epigenetic footprints for neurodegenerative and autoimmune conditions: a comparative analysis.

Hunter, E, et. al.,
The Lancet Neurology Conference

October 21, 2016

http://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/2016-LNC-Epigenetic-footprints-for-neurodegenerative-and-autoimmune-conditions.pdf

Epigenetic signatures and early detection of neurodegenerative diseases.

Salter, M., et. al.,
The Lancet Neurology Conference

October 19, 2016

http://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/2016-LNC-Epigenetic-signatures-and-early-detection-of-neurodegenerative-diseases.pdf

Chromosome conformation capture to discover candidate epigenetic markers of Multiple Sclerosis disease severity.

Sangurdekar, D., et. al.,
32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis

September 15, 2016

http://onlinelibrary.ectrims-congress.eu/ectrims/2016/32nd/146797/tatiana.plavina.chromosome.conformation.capture.to.discover.candidate.html?f=m3

Epigenetic profile of chromosome conformation signatures underlying multiple sclerosis and its severity.

Joesph, JP., et. al.,
32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis

September 14, 2016

http://onlinelibrary.ectrims-congress.eu/ectrims/2016/32nd/146441/joyce.joseph.epigenetic.profile.of.chromosome.conformation.signatures.html?f=m3

Systemic Epigenetic Biomarkers for ALS Improve Early Diagnosis, Treatment and Trials.

Jeznach, M.
International Pharmaceutical Industry

April 20, 2016

https://issuu.com/mark123/docs/ipi_march2016_web/45

Epigenetic Chromosome Conformations Predict MTX Responsiveness in Early Rheumatoid Arthritis Patients.

Carini, C., et. al.,
Annual Meeting of the American College of Rheumatology

November 7, 2015

http://acrabstracts.org/abstract/epigenetic-chromosome-conformations-predict-mtx-responsiveness-in-early-rheumatoid-arthritis-patients/

Development of Epigenetic Profiling of ALS Patients with Chromosome Conformation Biomarkers Offers Novel Signatures for Non-invasive Diagnostic and Prognostic Stratifications.

Hunter, E., et. al.,
14th Annual Northeast Amyotrophic Lateral Sclerosis Consortium

November 3, 2015

http://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/ALSNEALS2015.pdf